Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

European Heart Journal

Volumn 19, Issue 10, 1998, Pages 1434-1503

  Wood, David ^a   De Backer, Guy ^b   Faergeman, Ole ^b   Graham, Ian ^b   Mancia, Giuseppe ^b   Pyörälä, Kalevi ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE

Author keywords

Atherosclerosis; Coronary heart disease; Primary prevention; Risk factors; Secondary prevention

Indexed keywords

ATHEROSCLEROSIS; CLINICAL PRACTICE; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

EID: 0032189666     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1243     Document Type: Review

References (476)

1. [1] Sans S, Kesteloot H, Kromhout D on behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-48.
2. [2] Marmot MG, Shipley MJ, Rose G. Inequalities in death-specific explanations of a general pattern? Lancet 1984; ii: 1003-6.
3. [3] Marmot MG, Kogevinas M, Elston MA. Socioeconomic status and disease. WHO Reg Publ Eur Ser 1991; 37: 113-46.
4. [4] Jacobsen BK, Thelle DS. Risk factors for coronary heart disease and levels of education. The Tromso Heart Study. Am J Epidemiol 1988; 127: 923.
5. [5] Winkleby MA, Fortmann SP, Barett DC. Social class disparaties in risk factors for disease. Eight-year prevalence patterns by level of education. Prev Med 1990; 19: 1-12.
6. [6] Luepker RV, Rosamond WD, Murphy R et al. Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart Survey. Circulation 1993; 88 (part 1): 2172-9.
7. [7] Wagenknecht LE, Perkins LL, Cutter GR et al. Cigarette smoking is strongly related to educational status. The CARDIA Study. Prev Med 1990; 19: 158-69.
8. [8] Osler M. Social class and health behaviour in Danish adults: a longitudinal study. Public Health 1993; 107: 251-60.
9. [9] Bolton-Smith C, Smith WCS, Woodward M, Tunstall-Pedoe H. Nutrient intakes of different social-class groups. Results from the Scottish Heart Health Study (SHHS). Br J Nutr 1991; 65: 321-35.
10. [10] Nourjah P, Wagener DK, Eberhardt M, Orowitz AM. Knowledge of risk factors and risk behaviours related to coronary heart diseases among blue and white collar males. J Public Health Policy 1994; 15: 443-59.
11. [11] Sobal J. Obesity and socioeconomic status: A framework for examining relationships between physical and social variables. Med Anthrop 1991; 13: 231-47.
12. [12] Burke GL, Savage PJ, Manorio TA et al. Correlates of obesity in younger black and white women: The CARDIA Study. Am J Pub Health 1992; 82: 1621-5.
13. [13] Orth-Gomer K, Rosengren A, Wilhemsen L. Lack of social support and incidence of coronary heart disease in middleage Swedish men. Psychos Med 1993; 55: 37-43.
14. [14] Bosma H, Marmot MG, Hemingway H, Nicholson A, Brunner EJ, Stanfeld S. Low job control and risk of coronary heart disease in the Whitehall II (prospective cohort) study. Br Med J 1997; 314: 558-65.
15. [15] Theorell T, Tsutsumi A, Hallqvist J et al. Decision latitude, job strain and myocardial infarction: A study of working men in Stockholm. Am J Pub Health 1998; 88: 382-8.
16. [16] Chesney AM. Social support and heart disease in women. Implications for intervention. In: Orth-Gomer K, Chesney AM, Wenger NK, eds. Women, Stress and Heart Disease. Mahwah, New Jersey: Lawrence Arlbaum Associates, Publishers, 1998: 165-84.
17. [17] Lynch JW, Kaplan GA, Cohen RD et al. Do cardiovascular risk factors explain the relation between socio-economic status, risk of all cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996; 144: 934-42.
18. [18] Marmot MG, Bosma H, Hemingway H, Brunner E, Stansfeld S. Contribution of job control and other risk factors to social variations in coronary heart disease incidence. Lancet 1997; 350: 235-9
19. [19] Wamala SP, Orth-Gomer K. Interfaces of human biology and social organization: Challenges for future research. A National Report on: Promoting Research on Inequality in Health in Sweden, 1998.
20. [20] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31; Atherosclerosis 1994; 110: 121-61.
21. [20] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31; Atherosclerosis 1994; 110: 121-61.
22. [21] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevence ischemické choroby srdecní v klinické praxi. Cor Vasa 1995; 37:K123-25
23. [22] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Cyprus Med J 1995; 13: 3-12.
24. [23] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prévention de la maladie coronarienne en pratique clinique. Coeur Vaisseaux 1995; 10: 1493-535.
25. [24] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Hellenic J Cardiol 1995; 36: 228-38.
26. [25] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Koronãrãs sirds slimibas profilakse kliniskã praksê. Eiropas Kardiologu biedrivas, Eiropas Aterosklerozes biedribas un Eiropas Hipertensijas biedribas kopêjãa darba grupas ietikumi. Latvias Arsts 1995; 10: 6-12.
27. [26] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Hjerteforum 1995; 2: 23-33.
28. [27] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Material Metodologic - Prevenirea Cardiopatiei Ischemice in Practica Cliniã. Recomandãrile grupuliu de experti ai Societãtii Europene de Cardiologie, ai Societãtii Europene de Aterosclerozã si ai Societãtii Europene de Hipertensiune. Rev Rom Cardiol 1995; 1: 25-9.
29. [28] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevención de la enfermedad coronaria en la práctica clínica. Recomendaciones del Grupo de Trabajo de la Sociedad Europea de Cardiologia (ESC), Sociedad Europea de Aterosclerosis (EAS) y Sociedad Europea de Hipertensión (ESH). Rev Esp Cardiol 1995; 48: 773-80
30. [29] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Koroner Kalp Hastahgindan Korunma ve Tedaviye Iliskin Ulusal Kilavuz. Türk Kardiyol Dern Ars 1995; 23: 213-24.
31. [30] Kühn P. Die Herzrisikotabelle fass für den niedergelassene Arzt die wichtigsten Fakten der Herz-Kreislaufprävention zusammen. J Austr Med Assoc 1996; 10: 28-33.
32. [31] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prévention de la maladie coronarienne en pratique clinique: résumé pour les cliniciens. J Cardiologie 1996; 8: 71-80.
33. [32] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevencija koronarne bolesti srca u klinickoj praksi. Preporuke Radne skupine Europskoga kardioloskog drustva, Europskoga drustva za aterosklerozu I Europskoga drustva za hipertenziju. J Croat Med Assoc 1996; 108: 21-226.
34. [33] Suomen Sisätautilääkärien Yhdistyksen, Suomen Kardiologisen Seuran, Suomen Verenpaineyhdistyksen, Kunnallislääkärit-yhdistyksen, Suomen Teollisuusläketieteen Yhdistyksen ja Suomen Sydäntauytiliiton työryhmä. Sepelvaltimotaudin ehkäisy Käytännön lääikärintyössä. European Society of Cardiology. European Atherosclerosis Societyn ja European Societyn of Hypertensionin Task Forcen suosituksen suomalainen sovellus. Suom Lääkäril 1996; 51: 783-802.
35. [34] Östor E. A coronariabetegség prevenci↑oja a klinikai gyakorlatban. CARDIOSCAN 1996; 2: 43-8.
36. [35] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Ir Coll Phys Surg 1996; 254: 249-56.
37. [36] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevenzione della malattia coronarica nella pratica clinica. Raccomandazioni della Task Force costituita da European Society of Cardiology, European Atherosclerosis Society e European Society of Hypertension. CARDIOLOGIA 1996; 412: 149-82.
38. [37] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevenirea Cardiopatiei Ischemice in Practica Clinica (Recomandarile grupului de experti al societãtilor Europene de Cardiologie, Ateroscleroza si Hipertensiune. Curier Medical 1996; 2: 56-9.
39. [38] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Zapobieganie chorobie wiencowej. Zalecenia Porozimienia zawartego przez Europejskie Towarzystwo Kardiologiczne, Europejskie Towarzystwo Badan nad Miazdzy-ca I Europejskie Towarzystwo Nadcisnieniowe. Zdrowe Serce 1996; 3: 4-20.
40. [39] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Recomendações na Prevenção Primária e Secundária da Doença das Coronárias. Sociedade Portuguesa de Cardiologia. Aterosclerose e Hipertensão 1996; 4: 7-40.
41. [40] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Russ Med Soc Cardiol 1996; 1-60.
42. [41] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevencia ischemickej choroby srdca v klnickej praxi -suhrn pre klinikov. Odporúcania Komisie Európskej Kardiologickej Spolocnosti, Európskej Spolocnosti pre Aterosklerózu a Európskej Spolocnosti pre Hypertenziu. Noninvas Cardiol 1996; 52: A3-A9.
43. [42] Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Ukr J Cardiol 1996; 5: 81-4.
44. [43] Smith SC, Blair SN, Criqui MH et al. AHA Medical/ Scientific Statement. Preventing Heart Attack and Death in Patients with Coronary Disease. Circulation 1995; 92: 2-4.
45. [44] Fuster V, Pearson TA. 27th Bethesda Conference: Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. J Am Coll Cardiol 1996; 27: 957-1047.
46. [45] EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through intervention to reduce events. Eur Heart J 1997; 18: 1569-92.
47. [46] Bowker TJ, Clayton TC, Ingham J et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease - ASPIRE. Heart 1996; 75: 334-42.
48. [47] The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
49. [48] Sacks FM, Pfeffer MA, Moye L et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
50. [49] LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474-9.
51. [50] Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
52. [51] Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM. Primary prevention of acute coronary events with lovastatin in menand women with average cholesterol levels: results of AFCAPS/TEXCAPS. Air Force/Texas Coronary Atherosclerosis Study. JAMA 1998; 279: 1615-22.
53. [52] Grundy SM, Baladt GJ, Criqui MH et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. Circulation 1997; 95: 1683-5.
54. [53] Grundy SM, Balady GJ, Criqui MH et al. Guide to Primary Prevention of Cardiovascular Diseases. Circulation 1997; 95: 2329-31.
55. [54] Pearson T, Rapaport E, Criqui M et al. Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. Circulation 1994; 90: 3125-33.
56. [55] Prevention of coronary heart disease. Report of a WHO Expert Committee. WHO Technical Report Series 678. Geneva: World Health Organization, 1982.
57. [56] Barker DJP. Fetal origins of coronary heart disease. Br Med J 1995; 311: 171-4.
58. [57] Cardiovascular disease risk factors: new areas for research. Report of a WHO Scientific Group. WHO Technical Report Series 841. Geneva: World Health Organization, 1994.
59. [58] Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: A statement for health professionals. Circulation 1991; 83: 356-62.
60. [59] Ettinger WH, Wahl PW, Kuller LH et al, for the CHS Collaborative Research Group. Lipoprotein lipids in old people. Results from Cardiovascular Health Study. Circulation 1992; 86: 858-69
61. [60] Kornitzer M, De Backer G, Dramaix M et al. Belgian Heart Disease Prevention Project: Incidence and mortality results. Lancet 1983; I: 1066-70.
62. [61] Hjermann I, Velve Byre K, Holme I, Leren P. Effects of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; II: 1303-10.
63. [62] WHO European Collaborative Group. European Collaborative Trial of Multifactorial prevention of coronary heart disease: final report of the 6-years results. Lancet 1986; I: 869-72.
64. [63] Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-77
65. [64] Wilhemsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986; 7: 279-88.
66. [65] Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. Findings related to a priori hypotheses of the trial. JAMA 1990; 263: 1795-801.
67. [66] De Backer G, Kornitzer M, Dramaix M et al. The Belgian Heart Disease Prevention Project: 10-year mortality follow-up. Eur Heart J 1988; 9: 238-42.
68. [67] Rose G. WHO European Collaborative trial of multifactorial prevention of coronary heart disease. Lancet 1987; I: 685.
69. [68] Clarke R, Frost C, Collins R et al. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. Br Med J 1997; 314: 112-7.
70. [69] Diet, nutrition and prevention of chronic diseases. Report of a WHO Study Group. WHO Technical Report Series 797. World Health Organization. Geneva: 1990.
71. [70] Van Poppel G, on behalf of the TRANSFAIR Study Group. Intake of trans fatty acids in western Europe: the TRANSFAIR Study. Lancet 1998; 351: 1099.
72. [71] Katan MB, Grundy SM, Willett WC. Beyond low fats. Clinical debate. N Engl J Med 1997; 337: 563-7.
73. [72] Miettinen TA, Naukkarinen V, Huttunen J, Mattila S, Kumlin T. Fatty acid composition of serum lipids predicts myocardial infarction. Br Med J 1982; 285: 993-6.
74. [73] Wood DA, Riemersma RA, Butler S et al. Linoleic and eicosapentaenoic acids in adipose tissue and platelets and risk of coronary heart disease. Lancet 1987; i: 177-83.
75. [74] De Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
76. [75] Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish and fibre intakes on death and myocardial re-infarction: diet and re-infarction trial (DART). Lancet 1989; ii: 757-61.
77. [76] De Deckere EAM, Korver O, Verschuren PM, Katan MB. Health aspects of fish and N-3 polyunsaturated fatty acids from plant and animal origin. Eur J Clin Nutr (in press).
78. [77] Ness A, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997; 26: 1-13.
79. [78] Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
80. [79] Stampfer MJ, Hennekens CH, Manson JE et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
81. [80] Rimm EB, Stampfer MJ, Ascherio A et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
82. [81] Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1993; 3: 194-202.
83. [82] Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease. The Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
84. [83] The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of Vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
85. [84] Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
86. [85] Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
87. [86] Rapola JM, Virtamo J, Ripatti S et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
88. [87] Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
89. [88] Singh RB, Rastogi SS, Verma R et al. Randomised controlled trial of a cardioprotective diet in patients with a recent acute myocardial infarction: results of one year follow-up. Br Med J 1992; 304: 1015-9.
90. [89] Huijbregts P, Feskens E, Räsänen L et al. Dietary pattern and 20 year mortality in elderly men in Finland, Italy, and the Netherlands: Longitudinal cohort study. Br Med J 1997; 315: 13-7.
91. [90] Trichopoulou A, Kouris-Blazos A, Wahlqvist ML et al. Diet and overall survival in elderly people. Br Med J 1995; 311: 1457-60.
92. [91] The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-83.
93. [92] INTERSALT Cooperative Research Group. INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Br Med J 1988; 297: 319-28.
94. [93] Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117-24.
95. [94] Björntorp P. Obesity. Lancet 1997; 350: 423-6.
96. [95] Prevention and management of the global epidemic of obesity. Report of the WHO consultation on obesity (Geneva, June 3-5, 1997) Geneva: World Health Organization, 1998.
97. [96] Seidell JC. Dietary fat and obesity: an epidemiologic perspective. Am J Clin Nutr 1998; 67 (Suppl): 546S-50S.
98. [97] Pate RR, Blair SN, Haskell WL et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
99. [98] Bartechi CE, MacKenzie TD, Schrier RW. The human costs of tobacco use (first of two parts). N Engl J Med 1994; 330: 907-12.
100. [99] MacKenzie TD, Bartechi CE, Schrier RW. The human costs of tobacco use (second of two parts). N Engl J Med 1994; 330: 975-80.
101. [100] Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242-9.
102. [101] Manson JE, Tosteson H, Ridker PM et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406-16.
103. [102] Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and the risk of myocardial infarction in women and men: longitudinal population study. Br Med J 1998; 316: 1043-7.
104. [103] Kawachi J, Colditz GA, Stampfer MJ et al. Smoking cessation in relation to total mortality rates in women. Ann Intern Med 1993; 119: 992-1000.
105. [104] Dwyer JH. Exposure to environmental tobacco smoke and coronary risk. Circulation 1997; 96: 1403-7.
106. [105] Liam TH, He Y. Passive smoking and coronary heart disease: a brief review. Clin Exp Pharmacol Physiol 1997; 24: 993-6.
107. [106] Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. Br Med J 1997; 315: 973-82.
108. [107] Keys A, ed. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
109. [108] Yano K, Reed DM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program: Relationship to biological and lifestyle characteristics. Am J Epidemiol 1984; 119: 653-66.
110. [109] Hammond EC, Garfinkel L. Coronary heart disease, stroke and aortic aneurysm: factors in the etiology. Arch Environ Health 1969; 19: 167-82.
111. [110] Poikolainen K. Alcohol and mortality: a review. J Clin Epidemiol 1995; 48: 455-65.
112. [111] Duffy J. Alcohol consumption and all-cause mortality. Int J Epidemiol 1995; 24: 100-5.
113. [112] Thun MJ, Peto R, Lopez AD, Monaco JH, Henley J, Heath CW, Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S adults. N Engl J Med 1997; 337: 1705-14.
114. [113] Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol; 13 years' observations on male British doctors. Br Med J 1994; 309: 911-8.
115. [114] Shaper AG, Wannamethee G, Walker M. Alcohol and coronary heart disease: a perspective from the British Regional Heart Study. Int J Epidemiol 1994; 23: 482-94.
116. [115] Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? Br Med J 1996; 312: 731-6.
117. [116] Hein HO, Suadicani P, Gyntelberg F. Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. Br Med J 1996; 312: 136-41.
118. [117] Keil U, Chambless LE, Döring A, Filipiak B, Stieber J. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology 1997; 8: 150-6.
119. [118] Rehm JT, Bondy SJ, Sempos CT, Vuong CV. Alcohol consumption and coronary heart disease morbidity and mortality. Am J Epidemiol 1997; 146: 495-501.
120. [119] Renaud S, Beswick AD, Fehily AM, Sharp DS, Elwood PC. Alcohol and platelet aggregation: the Caerphilly prospective heart disease study. Am J Clin Nutr 1992; 55: 1012-7.
121. [120] Hendricks HFJ, Veenstra J, Velthuisnte Wierik EJM, Shaafsma J, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J 1994; 308: 1003-4.
122. [121] Klatsky AL. Alcohol, coronary heart disease, and hypertension. Ann Rev Med 1996; 47: 149-60.
123. [122] Report of a Joint Working Group of the Royal Colleges of Physicians, Psychiatrists and General Practitioners. Alcohol and heart in perspective. Royal College of Physicians of London, London 1995.
124. [123] Suhonen O, Aromaa A, Reunanen A, Knekt TP. Alcohol consumption and sudden coronary death in middle-aged Finnish men. Acta Med Scand 1987; 221: 335-41.
125. [124] Kauhanen J, Kaplan GA, Goldberg DE, Salonen JT. Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study. Br Med J 1997; 315: 846-51.
126. [125] Larsson B. Obesity and body fat distribution as predictors of coronary heart disease. In: Marmot M, Elliott P, eds. Coronary heart disease epidemiology. From aetiology to public health. Oxford University Press, 1992: 233-41.
127. [126] Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change, and coronary heart disease in women - risk within the 'normal weight range'. JAMA 1995; 273: 461-5.
128. [127] Rimm EB, Stampfer MJ, Giovannucci E et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995; 141: 1117-27.
129. [128] Spataro JA, Dyer AR, Stamler J, Shekelle RB, Greenlund K, Garside D. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J Clin Epidemiol 1996; 49: 849-57.
130. [129] Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996; 93: 1372-9.
131. [130] Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle-aged men. Br Med J 1997; 314: 1311-7.
132. [131] Harris TB, Launer LJ, Madans J, Feldman JJ. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. Br Med J 1997; 314: 1791-4.
133. [132] Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
134. [133] Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary mortality in older women. Ann Epidemiol 1993; 3: 35-41.
135. [134] Folsom AR, Kaye SA, Sellers TA et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993; 269: 483-7.
136. [135] Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality in healthy middle-aged Norwegian men. N Engl J Med 1993; 328: 553-7.
137. [136] Paffenbarger Jr R, Hyde RT, Wing Al, Lee I-Mlu, Jung DL, Kampert JB. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-45.
138. [137] Blair SN. Changes in physical fitness and all cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995; 73: 1093-8.
139. [138] Rosengren A, Wilhemsen L. Physical activity protects against coronary death and death from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. Ann Epidemiol 1997; 7: 69-75.
140. [139] Folsom AR, Arnett DK, Hutchinson RG, Liao F, Clegg LX, Cooper LS. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sports Exerc 1997; 29: 901-9.
141. [140] Wannamethee SG, Shaper AG, Walker M. Changes in physical activity mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603-8.
142. [141] Physical activity and health. A report of the surgeon general. US DHHS 1996.
143. [142] Goldbourt U. Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years. World Rev Nutr Diet 1997; 82: 229-39.
144. [143] Leon AS, Myers MT, Connett J. Leisure time physical activity and the 16 year risks of mortality from coronary heart disease and all causes in the multiple risk factor intervention trial (MRFIT). Int J Sports Med 1997; 18 (Suppl 3): 208-15.
145. [144] Shaper AG, Wannamethee G, Walker M. Physical activity hypertension and risk of heart attack in men without evidence of ischaemic heart disease. J Human Hypertens 1994; 8: 3-10.
146. [145] Blair SN, Kampert JB, Kohl HW et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all cause mortality in men and women. JAMA 1996; 276: 205-10.
147. [146] Pate RR, Pratt M, Blair SN et al Physical activity and public health: a recommendation from the Centre for Disease Control and prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
148. [147] Wenger NK, Froelicher ES, Smith LK et al. Cardiac rehabilitation as secondary prevention. Clinical practice guidelines. DHHS Agency for Health Care Policy and Research, NHLBI, AHCPRR, publication no. 96-0673, 1995.
149. [148] Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RY, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion - protection against triggering by regular exertion. N Engl J Med 1993; 329: 1677-83.
150. [149] Willich SN, Lewis M, Lovel H, Arnte H-K, Schubert F, Schröder R. Physical exertion as trigger of acute myocardial infarction. N Engl J Med 1993; 329: 1684-90.
151. [150] Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988; 260: 945-50.
152. [151] O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-44.
153. [152] Orth-Gomer J, Chesney MA. Social stress/strain and heart disease in women. In: Desmond GJ, Wenger NK, eds. Women and Heart Disease. Guildford & King's Lynn: Biddies Ltd, 1997: 407-20.
154. [153] Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction and total mortality in a community sample. Circulation 1996; 93: 1976-80.
155. [154] Anda R, Williamson D, Jones D, Macera C, Baker E, Glassman A. Depressed affect hopelessness and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993; 4: 285-94.
156. [155] Williams RB, Haney TL, Lee KL, Kong YH, Blumenthal JA, Whalen RE. Type A Behaviour, hostility, and coronary atherosclerosis. Psychos Med 1980; 42: 539-49.
157. [156] Barefoot JC, Dahlstrom WG, Williams RB. Hostility, CHD incidence and total mortality: A 25-Year follow-up Study of 255 physicians. Psychos Med 1983; 45: 59-63.
158. [157] Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
159. [158] Everson SA, Kauhanen J, Kaplan GA et al. Hostility and increased risk of mortality and acute myocardial infarction. The mediating role of behavioural risk factors. Am J Epidemiol 1997; 146: 142-52.
160. [159] Brunner E, Smith GD, Marmot M et al. Childhood social circumstances and psychological and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008-13.
161. [160] Rosengren A, Wilhemsen L, Welin L, Tsipogiaanni A, Teger-Nilsson AC, Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. Br Med J 1990; 300: 634-8.
162. [161] Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562-4.
163. [162] Krittayaphong R, Cascio WE, Light KC et al. Heart rate variability in patients with coronary artery disease. Differences in patients with higher and lower depression scores. Psychosom Med 1997; 59: 231-5.
164. [163] McCraty R, Atkinson M, Tiller WA, Rein G, Watkins AD. The effects of emotions on short-term power spectrum analysis of heart rate variability. Am J Cardiol 1995; 76: 1089-93.
165. [164] Mittleman AM, Maclure M, Nachmani M et al. Educational attainment, anger and the risk of triggering myocardial infarction onset. Arch Intern Med 1997; 157: 769-75.
166. [165] Oldenburg B, Graham-Clarke P, Shaw J, Walker S. Modification of health behavior and lifestyle mediated by physicians. In: Orth-Gomer K, Schneiderman N, eds. Behavioral medicine approaches to cardiovascular disease prevention. Mahwah, New Jersey: Lawrence Arlbaum Associates, Publishers, 1996: 203-26.
167. [166] Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336 (87708): 129-33.
168. [167] Burell G. Behavioral medicine interventions in secondary prevention of coronary heart disease. In: Orth-Gomer K, Schneiderman N, eds. Behavioural medicine approaches to cardiovascular disease prevention. Mahwah, New Jersey: Lawrence Arlbaum Associates, Publishers, 1996: 227-36.
169. [168] McMahon R, Peto R, Cuttler J et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
170. [169] Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-6.
171. [170] The Prospective Cardiovascular Münster Study (PROCAM). Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-24.
172. [171] Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085-91.
173. [172] Stamler R, Stamler Y, Grimm R et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial. The Hypertension Control Program. JAMA 1987; 257: 1484-91.
174. [173] Stamler R, Stamler Y, Gosch FC et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized controlled trial. JAMA 1989; 262: 1801-7.
175. [174] Hypertension Prevention Trial Research Group. Hypertension Prevention Trial: Three-year effects of dietary changes on blood pressure. Arch Intern Med 1990; 150: 153-62.
176. [175] Jula A, Rönnemaa T, Rastas M, Karvetti R-L, Mäki Y. Long-term non-pharmacological treatment for mild to moderate hypertension. J Intern Med 1990; 227: 413-21.
177. [176] Langford HG, Davis B, Oberman A et al. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. Hypertension 1991; 17: 210-7.
178. [177] Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett Y. The trial of Antihypertensive Interventions and Management (TAIM) Study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med 1992; 152: 131-6.
179. [178] Chalmers J, Morgan T, Doyle A et al. Australian National Health and Medical Research Council Dietary Salt Study in Mild Hypertension. J Hypertens 1986; 4 (Suppl 6): S629-S637.
180. [179] The Trials of Hypertension Prevention Collaborative Research Group. The effects of non-pharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention. Phase I. JAMA 1992; 267: 1213-20.
181. [180] Grimm Jr RH, Grandits GA, Cutler JA et al., for the TOHMS Research Group. Relationship of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638-48.
182. [180] Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-45.
183. [182] Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
184. [183] MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence of 1994. Vasc Med Biol 1994; 4: 265-71.
185. [184] Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-8.
186. [185] Mancia G, Grassi G. Considerations on current and future trials in hypertension. Blood Pressure 1996; 5: 327-32.
187. [186] Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull N Y Acad Med 1978; 54: 573-91.
188. [187] Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. Adverse effects of antihypertensive medications in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis 1986; 29 (Suppl 1): 73-88.
189. [188] Lindholm L, Ejlertsson G, Schersten B. High risks of cerebrocardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59 year old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216: 251-9.
190. [189] Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure 1992; 1: 205-11.
191. [190] Sytkowski PA, D'Agostino RB, Berlanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697-703.
192. [191] Dahlöf B, Lindholm LG, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension? Lancet 1991; 338: 1281-5.
193. [192] MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-12.
194. [193] Amery A, Birkenhäger W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54.
195. [194] Coope J, Warrender TS. Randomized trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-51.
196. [195] Thijs L, Fagard R, Lijnen P, Staessen Y, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103-9.
197. [196] Staessen J, Amery A, Fagard R. Isolated stystolic hypertension in the elderly. J Hypertens 1990; 8: 393-405.
198. [197] Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension, the Framingham Study. Circulation 1980; 61: 1179-82.
199. [198] SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
200. [199] Staessen JA, Fagard R, Thijs L et al, for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757-64.
201. [200] D'Agostino RB, Belanger AY, Kannel WB, Cruickshank JM. Relationship of low diastolic blood pressure to coronary heart disease in the presence of myocardial infarction: the Framingham study. Br Med J 1991; 303: 385-9.
202. [201] Browner WS, Hulley SB. Effect of risk factor status on treatment criteria. Implications of hypertension trials. Hypertension 1989; 13 (Suppl 1): S51-S56.
203. [202] Flack JM, Neaton J, Grimm Jr R et al, for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92: 2437-45.
204. [203] Cruickshank JM. Beta-blockers: primary and secondary prevention. J Cardiovasc Pharmacol 1992; (Suppl 11): S55-S69.
205. [204] The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990; 66: 331-401.
206. [205] Fourth International Study of Infarct Survival. Protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. ISIS-4 Collaborative group. Am J Cardiol 1991; 68: 87D-100D.
207. [206] Polese A, De Cesare N, Montorsi P et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation 1991; 83: 845-53.
208. [207] Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-500.
209. [208] Davey-Smith G, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol and mortality: The Whitehall Study. JAMA 1992; 267: 70-6.
210. [209] Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. Br Med J 1991; 303: 276-82.
211. [210] Ulvenstam G, Bergstrand R, Johansson S et al. Prognostic importance of cholesterol levels after myocardial infarction. Prev Med 1984; 13: 355-66.
212. [211] Pekkanen J, Linn S, Heiss J et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990; 322: 1700-7.
213. [212] Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann Intern Med 1991; 115: 687-93.
214. [213] West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
215. [214] Pedersen TR, Olsson AG, Færgeman O et al for the Scandinavian Simvastatin Survival Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
216. [215] Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Eur Heart J 1997; 18: 754-61.
217. [216] Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998: 19(Suppl A) A2-A11.
218. [217] Abbot RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein, total cholesterol screening and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8: 207-11.
219. [218] Pocock SJ, Shaper AG, Phillips AN. HDL-cholesterol, triglycerides and total cholesterol in ischaemic heart disease. Br Med J 1989; 298: 998-1002.
220. [219] Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relationships between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63: 42H-7H.
221. [220] Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Arch Intern Med 1992; 152: 56-64.
222. [221] Study Group of the European Atherosclerosis Society. Strategies for the prevention of coronary heart disease. Eur Heart J 1987; 8: 77-88.
223. [222] Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992; 2: 113-156; published also as a book, London: Current Medical Literature, 1993.
224. [223] A desk top guide to the management of risk factors for coronary heart disease. European Atherosclerosis Society, 1992.
225. [224] National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445.
226. [225] Austin MA. Plasma triglycerides as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 1989; 129: 249-59.
227. [226] Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.
228. [227] Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eightyear follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
229. [228] Nordestgaard BG. The vascular endothelial barrier -selective retention of lipoproteins. Curr Opin Lipidol 1996; 7: 269-73.
230. [229] Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. III. Genetic analysis of lipid levels in 176 families and delineation of a new, inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-68.
231. [230] Genest Jr JJ, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-33.
232. [231] Austin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc 1997; 56: 667-70.
233. [232] Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-5.
234. [233] Ericsson C-G, Nilsson J, Svane B, Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997; 80: 1125-9.
235. [234] Haffner SM, Applebaum-Bowden D, Wahl PW et al. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II and D, and lecithin cholesterol acyltransferase E: effect of smoking, alcohol and adiposity. Arteriosclerosis 1985; 5: 169-77.
236. [235] Robinson D, Ferns JA, Bevan EA, Stock J, Williams PT, Galton DJ. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis 1987; 7: 341-6.
237. [236] Manninen V, Tenkanen H, Koskinen P et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Disease Study. Implications for treatment. Circulation 1992; 85: 37-45.
238. [237] Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51.
239. [238] Frick MH, Syvanne M, Nieminen MS et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96: 2137-43.
240. [239] Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerosis coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-7.
241. [240] Sniderman AD, Shapiro S, Marpole DG, Skinner BF, Teng B, Kwiterovich Jr PO. Association of coronary atherosclerosis with hyperbetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low-density (B) lipoproteins. PNAS 1980; 77: 604-8.
242. [241] Sandholzer C, Saha N, Kark JD et al. Apo(A) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992; 12: 1214-26.
243. [242] Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-73.
244. [243] Fager G, Wiklung O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol 1997; 17: 3527-33.
245. [244] Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993; 306: 1367-73.
246. [245] Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90: 1056-69.
247. [246] Waters D, Higginson L, Gladstone P et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68.
248. [247] Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994; 344: 1182-6.
249. [248] MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet 1994; 344: 633-8.
250. [249] Pitt B, Mancini GBJ, Ellis SG, Osman HS, Park J-S, McGovern ME. Pravastatin limitation of atheroslcerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9.
251. [250] Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
252. [251] Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86.
253. [252] Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Am J Cardiol 1997; 79: 893-6.
254. [253] Post Coronary Artery By-Pass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery by-pass grafts. New Engl J Med 1997; 336: 153-62.
255. [254] Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Lancet 1984; 2: 600-4.
256. [255] Jacobs D, Blackburn H, Higgins M et al. Report of the Consensus on Low Blood Cholesterol: mortality associations. Circulation 1992; 86: 1046-60.
257. [256] Lewis B, Tikkanen MJ. Blood total cholesterol and mortality: causality, consequence and confounders. Am J Cardiol 1994; 73: 80-5.
258. [257] Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs. Br Med J 1992; 304: 431-4.
259. [258] Pedersen TR, Berg K, Cook TJ et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92.
260. [259] Miettinen TA, Pyörälä K, Olsson AG et al for the Scandinavian Simvastatin Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997; 96: 4211-8.
261. [260] Crouse 3rd JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305-10.
262. [261] Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
263. [262] Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.
264. [263] Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Eur Heart J 1996; 17: 1001-7.
265. [264] West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79: 756-62.
266. [265] Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20.
267. [266] Goldbourt U, Behar S, Reicher-Reis H et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909-15.
268. [267] Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
269. [268] Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes/Metab Rev 1987; 3: 463-524.
270. [269] Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-5.
271. [270] Yudkin JS, Blauth C, Drury P et al. Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. Diabet Med 1996; 13: S101-21.
272. [271] Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5: 294-315.
273. [272] Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-62.
274. [273] Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is . . . or is it? Lancet 1997; 350 (Suppl I): 4-9.
275. [274] Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-78
276. [275] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
277. [276] Alberti KGMM, Zimmet P, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and clarification of diabetes mellitus. Provisional Report of a WHO Consultation. Diabet Med 1998; 15: 539-53.
278. [277] Diabetes mellitus. Report of a WHO Study Group. Technical Report Series 646. Geneva: World Health Organization, 1985.
279. [278] Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-7.
280. [279] Klein R. Kelly West Lecture 1994: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68.
281. [280] Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7.
282. [281] Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354-9.
283. [282] Turner RC, Millns H, Neil HAW et al for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). Br Med J 1998; 316: 823-8.
284. [283] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetics on the development and progress of the long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
285. [284] Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Ann Med 1996; 28: 439-44.
286. [285] Malmberg K, Rydén L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
287. [286] Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus. Lessons learned from ACE inhibition. Circulation 1998; 97: 12-5.
288. [287] Manson JE, Golditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
289. [288] Stamler J, Vaccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes Care 1991; 14: 173-94
290. [289] Adlerbert AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary heart disease and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998; 21: 539-45.
291. [290] European Arterial Risk Policy Group on behalf of the International Diabetes Federation (European Region). A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med 1997; 14: 611-21.
292. [291] Fuller JH, Stevens LK, Chaturvedi N, Holloway JF. Anti-hypertensive therapy in diabetes mellitus. Cochrane Review (updated 28/08/1997).
293. [292] Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
294. [293] Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
295. [294] Mykkänen L, Rönnemaa T, Marniemi J Haffner SM Bergman R, Laakso M. Insulin sensitivity is not an important determinant of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264-71.
296. [295] Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemostasis 1997; 78: 656-60.
297. [296] Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol 1996; 7: 217-26.
298. [297] Boushey C, Beresford SAA, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
299. [298] Alfthan G, Pekkanen J, Jauhianen M et al. Relations of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
300. [299] Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in Multiple Risk Factor Interventional Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
301. [300] Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
302. [301] Harmon DL, Woodside JV, Yarnell JWG et al. The common 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med 1996; 89-571-7.182.
303. [302] Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylene-tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9, 179.
304. [303] Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin J. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
305. [304] Mead TW, Mellows S, Brozovic M et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
306. [305] Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183-6.
307. [306] Yarnell JWG, Baker IA, Sweetman PM et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart diseases; the Caerphilly and Speewell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
308. [307] Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIc and PAI-1 in European offspring: the EARS Study. Thromb Haemost 1994; 71: 434-40.
309. [308] Behague I, Poirier O, Nicaud V et al. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996; 93: 440-9.
310. [309] Meade TW. Fibrinogen and other clotting factors in cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic vascular disease, hemostasis, and endothelial function. New York: Marcel Dekker, 1992: 1-32
311. [310] Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
312. [311] Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-36.
313. [312] Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
314. [313] Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
315. [314] Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele specific increase in basal transcription of the PAI-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
316. [315] Ye S, Green FR, Scarabin PY et al. The 4G/5G genetic polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM. Thromb Haemost 1995; 74: 837-41.
317. [316] Thaulow E, Erikssen J, Sandvik K-L et al. Blood platelet count and function are related to total and cardiovascular health in apparently healthy men. Circulation 1991; 84: 613-7
318. [317] Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischaemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991; 83: 38-44.
319. [318] Wu KK. Genetic markers: genes involved in thrombosis. JCR 1997; 4: 347-52.
320. [319] Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
321. [320] Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217-9.
322. [321] Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
323. [322] The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
324. [323] Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 461-6.
325. [324] Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47.
326. [325] Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
327. [326] Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
328. [327] Koenig W, Froehlich M, Sund M et al. C-reactive protein (CRP) predicts the risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augsburg cohort study, 1984/85-1992. Circulation 1997; 96 (Suppl I): 1-99 (Abstr).
329. [328] Tracy R, Lomalue R, Psaty B et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
330. [329] Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-8.
331. [330] Mendall MA, Patel P, Asante M et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273-7.
332. [331] Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
333. [332] Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MK, Allen J. Plasma concentrations of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
334. [333] Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
335. [334] Muhlestein JB, Hammond EH, Carlquist JF et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
336. [335] Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
337. [336] Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomized trial of roxithromycin in non Q wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.
338. [337] Inman WHW, Vessey MF, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203-9.
339. [338] Mann JJ. Oral contraceptives and the cardiovascular risk. In: Oliver MF, ed. Coronary heart disease in young women. Edinburgh: Churchill Livingstone, 1978:184-94.
340. [339] Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. WHO Technical Report Series 877. Geneva: World Health Organization, 1998.
341. [340] Oliver MF, Boyd JS. Effect of bilateral ovariectomy on coronary artery disease and serum lipid levels. Lancet 1959; ii: 690-4.
342. [341] Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med 1959; 104: 908-13.
343. [342] Palmer JR, Rosenberg L, Shapiro S. Reproductive factors and risk of myocardial infarction. Am J Epidemiol 1992; 136: 408-16.
344. [343] Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinic's Program Follow-up Study. Circulation 1987; 75: 1002-9.
345. [344] Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 26: 47-63.
346. [345] Grady D, Rubin SH, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
347. [346] Wallentin L, Larsson-Cohn V. Metabolic and hormonal effects of postmenopausal oestrogen replacement treatment. II. Plasma lipids. Acta Endocrinol 1977; 86: 597-607.
348. [347] Wanl P, Walden C, Knoop R et al. Effect of oestrogen/ progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983; 308: 862-7.
349. [348] Cauley JA, La Parte R, Kuller L et al. Menopausal oestrogen use, high density cholesterol subfractions and liver function. Atherosclerosis 1983; 49: 31-9.
350. [349] Barrett-Connor E, Slone S, Greendale G et al. The Postmenopausal Estrogen/Projestin Intervention Study: primary outcomes in adherent women. Maturitas 1997; 27: 261-74.
351. [350] Brinton LA. The relationship of exogenous oestrogens to cancer risk. Cancer Detect Prev 1984; 7: 159-71.
352. [351] Shapiro S, Kelly J. Rosenberg L et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1955; 313: 969-72.
353. [352] Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54: 825-32.
354. [353] Wingo PA, Layde PM, Lee NC et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209-15.
355. [354] Bergkvist L, Adami HO, Persson J et al. The risk of breast cancer after oestrogen and oestrogen-progestin replacement. N Engl J Med 1989; 321: 193-7.
356. [355] Marenberg ME, Risch N, Berkman LF, Floderus B, De Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
357. [356] Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E allele and risk of coronary disease a meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250-5.
358. [357] Cambien F, Evans AE. The angiotensin-I converting enzyme (ACE) gene polymorphism and coronary heart disease. Eur Heart J 1995; 16 (Suppl K): 13-22.
359. [358] Montgomery HE, Clarkson P, Dollery CM et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997; 96: 741-7.
360. [359] Amant C, Bauters C, Bodart JC et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96: 56-60.
361. [360] Ribichini F, Steffenino G, Dallavalle A et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme a major risk factor and a marker of risk of coronary stent restenosis. Circulation 1998; 97: 147-54.
362. [361] Pinto YM, van Gilst WH, Kingma H, Schunkert H. Deletion-allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. J Am Coll Cardiol 1995; 25: 1622-6.
363. [362] Andersson B, Sylven C. The DD genotype of the angiotensin converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28: 162-7.
364. [363] Montgomery HE, Clarkson P, Nwose OM et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G453A polymorphism of the βfibrinogen gene. Arterioscler Thromb Vasc Biol 1996; 16: 386-91.
365. [364] Gardemann A, Schwartz O, Haberbosch W et al. Positive association of the βfibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77: 1120-6.
366. [365] De Maat MPM, Kastelein JJP, Jukema JW et al. 455G/A polymorphism of the βfibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
367. [366] Fumeron F, Betoulle D, Luc G et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995; 96: 1664-71.
368. [367] Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylene-tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
369. [368] Harmon DL, Woodside JV, Yarnell JWG et al. The common thermolabile variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med 1996; 89: 571-7.
370. [369] Cusi D, Barlassina C, Azzani T et al. Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7.
371. [370] Wilhelmsen L. Salt and hypertension. Clin Sci 1979; 57: 455S-8S.
372. [371] Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization, 1995.
373. [372] Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995; 311: 1401-5.
374. [373] Mancia G, Ferrari AU, Gregorini L et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96-104.
375. [374] Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261-7.
376. [375] Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring: use in hypertension research and clinical practice. Hypertension 1993; 21: 510-24.
377. [376] Pickering TG, James GD, Boddie C, Harsfield GA, Blank S, Laragh JH. How common is white coat hypertension. JAMA 1988; 259: 225-8.
378. [377] Mancia G, Bertinieri G, Parati G et al. Effects of blood pressure measurement by the doctor on patients' blood pressure and heart rate. Lancet 1983; 2: 695-8.
379. [378] Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9: 209-15.
380. [379] Mancia G, Sega R, Bravic C, De Vito G, Valagussa F, Cesana G, Zanchetti A. Ambulatory blood pressure normality:results from the PAMELA study. J Hypertens 1995; 13: 1377-90.
381. [380] Staessen J, Fagard R, Lijnen P, Thijs L, Van Hoof R, Amery A. Mean and range of ambulatory blood pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol 1991; 67: 723-7.
382. [381] Mancia G, Zanchetti A. Editor's corner: white-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens 1996; 14: 1049-52.
383. [382] McCall M, Elmfeldt D, Vedin A, Wilhelmsson C, Wedel H, Wilhemsen L. Influence of myocardial infarction on blood pressure and serum cholesterol. Acta Med Scand 1979; 206: 477-81.
384. [383] Yu HH, Ginsburg GS, Harris N, Rifai N. Evaluation and clinical application of a direct low-density lipoprotein cholesterol assay in normolipidemic and hyperlidemic adults. Am J Cardiol 1997; 80: 1295-9.
385. [384] Mbewn AD, Durrington PN, Bulleid S, Mackness MI. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apolipoprotein A1 and B lipids and c-reactive protein. Atherosclerosis 1993; 103: 65-71.
386. [385] Shankat N, Ashraf SS, Mackness MI, Mbewn AD, Bhatnagar D, Durrington PN. A prospective study of serum lipoproteins after coronary bypass surgery. Q J Med 1994; 87: 539-45.
387. [386] ESC Working Group on Exercise Physiology, Physiopathology and Electrocardiography. Guidelines for cardiac exercise testing. Eur Heart J 1993; 14: 969-88.
388. [387] Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behavior. Amer Psychologist 1992; 47: 1102-14.
389. [388] Prochaska JO, Vilicer WF, DiClemente CC, Fava J. Measuring processes of change: Application to the cessation of smoking. J Cons Clin Psychol 1988; 56: 520-5.
390. [389] Kottke TE, Battista RN, De Friese GH, Brekke ML. Attributes of successful smoking cessation interventions in medical practice: a meta-analysis of 39 controlled trials. JAMA 1988; 259: 2883-9.
391. [390] Law M, Tang JL. An analysis of effectiveness of interventions intended to help people stop smoking. Arch Int Med 1995; 155: 1933-41.
392. [391] Schwartz J. Review and evaluation of smoking cessation methods: the US and Canada 1978-1985. National Institute of Health Publication 87-2940. Washington, DC: US. Government Printing Office, 1987.
393. [392] Austoker J, Sanders D, Fowler G. Smoking and cancer: Smoking cessation. Br Med J 1994; 308: 1478-82.
394. [393] Ockene IS, Houston Miller N. Cigarette smoking, cardiovascular disease, and stroke. Circulation 1997; 96: 3243-7.
395. [394] Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-42.
396. [395] Joseph AM, Norman SM, Ferry LH et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792-8.
397. [396] Task Force of the Working Group on Cardiac Rehabilitation of the European Society of Cardiology. Long-term comprehensive care of cardiac patients. Eur Heart J 1992; 13 (Suppl C): 1-45.
398. [397] Fletcher GF. How to implement physical activity in primary and secondary prevention. Circulation 1997; 96: 355-7.
399. [398] Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. J Hypertens 1993; 11: 905-18.
400. [399] The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-45.
401. [400] Hypertension control. Report of a WHO Expert Committee. WHO Technical Report Series 862. Geneva: World Health Organization, 1996.
402. [401] Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of ecocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
403. [402] Casale PN, Devereaux RB, Milner M. Value of ecocardiographic left ventricular mass in protecting cardiovascular morbid events in hypertensive men. Ann Int Med 1986; 105: 173-8.
404. [403] Devereaux RB. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology. Diagnosis and Management. New York, NY: Raven Press, 1990: 359-77.
405. [404] Deckert T, Koford-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rassmudsen B, Jensen T. Microalbuminuria. Implications for micro-and macrovascular disease. Diabetes Care 1992; 15: 1181-91.
406. [405] Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of cardiovascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; II: 530-3.
407. [406] Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
408. [407] Maschio G, Alberti D, Janin G et al for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
409. [408] Giatras I, Lau J, Levey AS, for the Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337-45.
410. [409] Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744-50.
411. [410] Groppelli A, Giorgi DMA, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992; 10: 495-9.
412. [411] Furberg CD, Psaty BM, Cuttler GA. Blood pressure and cardiovascular disease. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersch BJ, eds. Evidence based cardiology. London: BMJ Books, 1998: 226-38.
413. [412] Mancia G, Grassi G. Combination treatment in antihypertensive drug trials (editorial). Cardiovasc Drug Ther 1997; 11: 517-8.
414. [413] Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens 1986; 4: 141-56.
415. [414] Gong L, Zhang W, Zhu Y et al. Shangai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237-45.
416. [415] Hansson L. The Captopril Prevention Project (CAPP): description and status. Am J Hypertens 1994; 7: 82S-3S.
417. [416] Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-3.
418. [417] D'Agostino RB, Belanger AY, Kannel WB, Cruickshank JM Relationship of low diastolic blood pressure to coronary heart disease in the presence of myocardial infarction. BMJ 1991; 303: 385-9.
419. [418] Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-7.
420. [419] Sacks FM, Moyé LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97: 1446-52.
421. [420] Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436-9.
422. [421] NIH Consensus Development Panel. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993; 269: 505-10.
423. [422] Gould AL, Rossouw JE, Santanello NC et al. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 1995; 91: 2274-82.
424. [423] Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
425. [424] European Policy Group 1998. A Desk-Top Guide to Type 1 (Insulin-dependent) Diabetes Mellitus. International Diabetes Federation (Europe) 1998.
426. [425] European Policy Group 1998. A Desk-Top Guide to Type 2 (Non-insulin-dependent) Diabetes Mellitus. International Diabetes Federation (Europe) 1998.
427. [426] American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998; 21 (Suppl 1): S23-S31.
428. [427] Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for Healthcare Professionals from the American Heart Association. Circulation 1997; 96: 2751-3.
429. [428] Yusuf S, Peto R, Lewis J, Collins R, Fleight P, Beta-blockade during and after myocardial infarction, an overview of the randomised trials. Prog Cardiovasc Dis 1984; 27: 335-71.
430. [429] Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in the light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7.
431. [430] Latini R, Maggioni A, Flather M, Slight P, Tognoni G, for the meeting participants. ACE inhibitor use in patients with myocardial infarction: Summary of evidence from clinical trials. Circulation 1995; 92: 3132-7.
432. [431] The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular election fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
433. [432] The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular election fractions. N Engl J Med 1992; 327: 685-91.
434. [433] SAVE Investigators. Effect of capropril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
435. [434] Cohn JN, Johnson G, Zlesche S et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1992; 325: 303-10.
436. [435] Fonarow GC, Chatimsky-Fallick C, Warnes Stevenson L et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure, the Hy-C trial. J Am Coll Cardiol 1992; 19: 842-50.
437. [436] The Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
438. [437] Gruppo Italiano per lo Studio delia Sopravivenza nell'infarto Miocardico. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
439. [438] Ambrosini E, Borghi C, Magani B. Survival of myocardial infarction. Long-term Evaluation (SMILE) Study; rationale, design, organisation and outcome definitions. Controlled Clin Trials 1994; 15: 201-10.
440. [439] ISIS-4. A randomized factorial trial assessing early oral captopril, mononitrate and intravenous magnesium sulphate in over 58050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infant Survival) Collaborative Group. Lancet 1995; 345: 66-85.
441. [440] Smith P, Arneson H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
442. [441] Needs and priorities in cardiac rehabilitation and secondary prevention in patients with coronary heart disease. WHO Technical Report Series 831. Geneva: World Health Organisation, 1993.
443. [442] American Heart Association. Cardiac Rehabilitation Programs. A Statement for Healthcare Professionals. Circulation 1994; 90: 1602-10.
444. [443] American Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for cardiac rehabilitation. (2nd edn) 1995. Champaign, Illnois: Human Kenetics Books.
445. [444] Gohlke H, Gohlke-Barwolf C. Cardiac rehabilitation. Eur Heart J 1998; 19: 1004-10.
446. [445] Pearson TA, Peters TD, Feury D. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study; attainment of goals for comprehensive risk reduction in patients with coronary disease in the US. J Am Coll Cardiol 1998; 31 (Suppl A): 186A (Abstr).
447. [446] Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997; 80: 45H-52H.
448. [447] Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behavior. Am Psychol 1992; 47: 1102-14.
449. [448] Debusk RF, Miller NH, Superko R, Dennis CA, Thomas RJ, Lew HT et al. A case-management system for coronary risk factor modification after myocardial infarction. Ann Intern Med 1994; 120: 721-9.
450. [449] Bandura A. The Exercise of Control. New York: Freeman, 1997.
451. [450] Fullard E, Weston S, Schofield T, Moher M. Managing established coronary heart disease. Br Med J 1997; 315: 69-70.
452. [451] Prochaska JO, Vilicer WF, DiClemente CC, Fava J. Measuring processes of change: Application to the cessation of smoking. J Cons Clin Psychol 1988; 56: 520-5.
453. [452] Kolonel LN, Lee J. Husband-wife correspondence in smoking, drinking and dietary habits. Am J Clin Nutrition 1981; 34: 99-104.
454. [453] Sackett DL, Anderson GD, Milner R, Feinleib M, Kannel WB. Concordance for coronary risk factors among spouses. Circulation 1975; 52: 589-95.
455. [454] Garrison RJ, Castelli WP, Feinleib M et al. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am J Epidemiol 1979; 110: 313-21.
456. [455] McGee HM, Graham T, Newton H, Morgan JH. The involvement of the spouse in cardiac rehabilitation. Ir J Psychol 1994; 15: 203-18.
457. [456] Pyke SDM, Wood DA, Kinmonth AL, Thompson SG, on behalf of the BFHS group. Changes in coronary risk factor levels in couples following lifestyle intervention: The British Family Heart Study. Arch Fam Med 1997; 6: 3254-360.
458. [457] Houston Miller N, Hill M, Kottke T, Ockeme IS. The Multilevel Compliance Challenge: Recommendations for a Call to Action. A Statement for Health Care Professionals. AHA Scientific Report. Circulation 1997; 95: 1085-90.
459. [458] Wexler L, Brundage B, Crouse I et al. Coronary artery calcification in pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for Health Professionals from the American Heart Association. Circulation 1996; 94: 1175-92.
460. [459] Solberg LA, Strong JP. Risk factors for atherosclerotic lesions: a review of autopsy studies. Atherosclerosis 1983; 3: 187-98.
461. [460] Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
462. [461] Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996; 313: 1440-4.
463. [462] Salonen R, Tervahauta M, Dalonen JT, Pekkanen J, Nissinen A, Karvonen MJ. Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern Finnish men. Prevalence and associations with cardiovascular diseases and risk factors. Arterioscler Thromb 1994; 14: 1631-40.
464. [463] Burke GL, Evans GW, Riley WA et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386-91.
465. [464] O'Leary DH, Polak JF, Kronmal RA et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996; 27: 224-31.
466. [465] Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Grouse 3rd JR. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991; 11: 786-94.
467. [466] Adams MR, Nagakomi A, Keech A et al. Carotid intima media-thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995; 92: 2127-34.
468. [467] Hulthe J, Wikstrand J, Emanuelsson H, Wiklund O, de Feyter PJ, Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke 1997; 28: 1189-94.
469. [468] De Groot E, Jukema JW, Montauban van Swijndregt AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31: 1561-7.
470. [469] Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11: 1245-9.
471. [470] Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1997; 146: 483-94.
472. [471] Furberg CD, Adans Jr HP, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87.
473. [472] Crouse 3rd JR, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
474. [473] Salonen R, Nyyssönen K, Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
475. [474] MacMahon S, Sharpe N, Gamble G et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. Lipid Trial Research Group. Circulation 1998; 97: 1784-90.
476. [475] The International Task Force for Prevention of Coronary-Heart Disease. Coronary heart disease: reducing the risk. The scientific background to primary and secondary prevention. A worldwide view. Nutr Metab Cardiovasc Dis 1998; 8 (in press).